- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Mobile C-Arm Device that May Accelerate Fluoroscopic and 3D CT Imaging
Offering ease of mobility and self-driving capabilities, the Ciartic Move C-arm device reportedly reduces the stress and potential for error associated with manual repositioning during intraoperative imaging with computed tomography and fluoroscopy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Ciartic Move C-arm device, which facilitate enhanced efficiency with intraoperative fluoroscopic and 3D cone-beam computed tomography (CT) imaging in the OR.
Providing full motorization from the C-arm down to the wheels of the device, the Ciartic Move has self-driving capabilities that may enable better consistency with intraoperative imaging and more automated imaging workflows, according to Siemens Healthineers, the manufacturer of the Ciartic Move.
In comparison to manual adjustments with conventional C-arm devices, the recently FDA-cleared Ciartic Move device reportedly offers self-driving capabilities and storage of up to 12 procedure-specific positions with associated imaging parameters, according to Siemens Healthineers, the manufacturer of the device. (Image courtesy of Siemens Healthineers.)
Noting the device’s ability to reduce the time and workforce capacity associated with manual adjustments of conventional C-arm devices, Siemens Healthineers pointed out that the Ciartic Move device allows clinicians to store up to 12 procedure-specific positions with associated imaging parameters.
“With the FDA clearance of the Ciartic Move, Siemens Healthineers proudly introduces our first self-driving mobile C-arm, which can provide much-needed relief for overtaxed operating room teams by automating and accelerating intraoperative imaging workflows to a previously unseen degree,” said April Grandominico, vice president for surgical therapies in the Advanced Therapies business at Siemens Healthineers North America.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
